International journal of nanomedicine · 2025
Evaluation of Self-Regulating Doped Ferrite Nanoparticles with Glucose, Chitosan, and Poly-Ethylene Glycol Coatings for Hyperthermia and Dual Imaging.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Negri Alessandro, Conti Anita, Milan Emil, Forlin Enrico, Gherlinzoni Filippo, Morana Giovanni, Gottardi Michele, Matteazzi Paolo, Speghini Adolfo, Bongers Andre, Marzola Pasquina
Аннотация
PURPOSE: This study investigates the theranostic potential of doped ferrite nanoparticles (NPs) with self-regulating temperature (SRT) properties, termed M55, coated with glucose (GM55), chitosan (CM55), and poly-ethylene glycol (PM55). The NPs were assessed for their physicochemical attributes, magnetic fluid hyperthermia (MFH) efficacy, dual-imaging capabilities in Magnetic Resonance Imaging (MRI) and Magnetic Particle Imaging (MPI), cytocompatibility, and cellular uptake.
METHODS: Physicochemical characterization was conducted using Fourier-transform infrared spectroscopy (FTIR), dynamic light scattering (DLS), and zeta potential measurements. The biocompatibility and cellular uptake were evaluated in MDA-MB-231 breast cancer cells, and MFH performance was tested in vitro. Following intravenous administration, MRI and MPI functionalities were analyzed through phantom studies and in vivo murine models.
RESULTS: Coated M55 NPs displayed high colloidal stability in water and effective functionalization. The specific absorption rate (SAR) of 24.4 ± 1.4 W/g confirmed their suitability for MFH applications. In vitro assays indicated excellent biocompatibility and substantial cellular internalization, with GM55 showing the highest uptake and MFH efficiency, reducing cell viability to 50.62 ± 3.92% post two treatment cycles, compared to 67.71 ± 6.11% (CM55) and 71.39 ± 5.84% (PM55). MRI transverse relaxivity (r2) values were notably high across all coatings, enhancing imaging contrast. MPI analysis demonstrated superior cell labeling sensitivity, with GM55 achieving the most pronounced detection. In vivo imaging confirmed effective NPs accumulation in the liver, underscoring their utility as dual MRI/MPI contrast agents (CAs).
CONCLUSION: Coated M55 NPs exhibit significant promise as multifunctional theranostic agents for cancer treatment. GM55, in particular, offers superior MFH efficacy and cellular uptake, while CM55 and PM55 may present unique advantages for alternative biomedical applications. The dual-imaging capabilities of these NPs provide a robust platform for real-time monitoring of distribution and therapeutic outcomes. Future investigations will focus on optimizing NPs formulations and expanding in vivo assessments to advance clinical translation.
METHODS: Physicochemical characterization was conducted using Fourier-transform infrared spectroscopy (FTIR), dynamic light scattering (DLS), and zeta potential measurements. The biocompatibility and cellular uptake were evaluated in MDA-MB-231 breast cancer cells, and MFH performance was tested in vitro. Following intravenous administration, MRI and MPI functionalities were analyzed through phantom studies and in vivo murine models.
RESULTS: Coated M55 NPs displayed high colloidal stability in water and effective functionalization. The specific absorption rate (SAR) of 24.4 ± 1.4 W/g confirmed their suitability for MFH applications. In vitro assays indicated excellent biocompatibility and substantial cellular internalization, with GM55 showing the highest uptake and MFH efficiency, reducing cell viability to 50.62 ± 3.92% post two treatment cycles, compared to 67.71 ± 6.11% (CM55) and 71.39 ± 5.84% (PM55). MRI transverse relaxivity (r2) values were notably high across all coatings, enhancing imaging contrast. MPI analysis demonstrated superior cell labeling sensitivity, with GM55 achieving the most pronounced detection. In vivo imaging confirmed effective NPs accumulation in the liver, underscoring their utility as dual MRI/MPI contrast agents (CAs).
CONCLUSION: Coated M55 NPs exhibit significant promise as multifunctional theranostic agents for cancer treatment. GM55, in particular, offers superior MFH efficacy and cellular uptake, while CM55 and PM55 may present unique advantages for alternative biomedical applications. The dual-imaging capabilities of these NPs provide a robust platform for real-time monitoring of distribution and therapeutic outcomes. Future investigations will focus on optimizing NPs formulations and expanding in vivo assessments to advance clinical translation.